Surrozen, Inc., a biopharmaceutical company, develops targeted regenerative antibodies to repair a range of tissues and organs damaged by serious disease, and to improve organ function. The company provides antibody platforms that functions as Wnt and R-spondin mimetics in stimulating cell and organ-specific tissue regeneration. Its programs include SZN-043, a liver-specific R-spondin-mimetic to stimulate hepatocyte regeneration in acute and chronic liver disease; and SZN-1326, an intestine-specific Wnt-mimetic to repair diseased epithelial tissue and address an unmet need in patients with inflammatory bowel disease. Surrozen, Inc. was incorporated in 2015 and is based in South San Francisco, California.